Bexagliflozin for patients with type 2 diabetes

This study wanted to evaluate the safety and effectiveness of bexagliflozin in patients with type 2 diabetes (T2D). The study found that this treatment was safe and significantly improved the outcomes of these patients.

Bexagliflozin is a new medication for treating T2D. It is part of a larger class of medications called SGLT2 inhibitors. These medications work by stopping excess sugar being reabsorbed into the blood by the kidneys. Instead, excess sugar from food is excreted through the urine. It is not known how well bexagliflozin works in patients with T2D who are treated with it long term.

This study had 286 patients with T2D. They all had an HbA1c (blood test measuring the average blood glucose in the past 3 months) of between 7% and 10%. They were not on any other medication. 145 of the patients were treated with bexagliflozin for 24 weeks. 141 of the patients took placebo pills.

After 24 weeks, the HbA1c of the patients was measured. On average the patients who took bexagliflozin decreased their HbA1c by 0.79% compared with the patients who took the placebo, who had an increase of 0.53%. The patients who took bexagliflozin also lost 3.22kg on average compared to the placebo group. The patients who took bexagliflozin saw improvements in their blood pressure also. The improvements in weight loss, HbA1c and blood pressure continued to be present 96 weeks after the trial.

There were no significant side effects noted with the use of this medication. There were 19 serious side effects reported, 2.8% in the bexagliflozin group and 8.5% in the placebo group. Urinary tract infections occurred more often in the placebo group (20.6%) than in the bexagliflozin group (14.5%)

Overall the study concluded that bexagliflozin improved HbA1c, weight, and blood pressure in patients with type 2 diabetes and was well tolerated.

This study was funded by Theracos Sub, LLC, the manufacturer of bexagliflozin.